Government tightens surveillance on GLP-1 weight-loss drug promotion amidst surrogate advertising concerns

Central government directs state regulators to enhance surveillance over GLP-1 drug promotion. Approved GLP-1 drugs are only for Type 2 diabetes and specific weight management. Advisories were issued to manufacturers and drug controllers regarding product information. Regulators must monitor supply chains and take action against diversion. Advertising platforms will be monitored for non-compliant promotions and violations.

Raccontata daeconomictimes.indiatimes.com